研究実績

英文原著

2024年

Real-World Outcomes of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Cohort Study.
Castro-Uriol D, Rios L, Enriquez-Vera D, Montoya J, Runciman T, Alarcón S, Zapata A, Hernández E, León E, Malpica L, Valcarcel B.
J Adolesc Young Adult Oncol. 2024;13:323-330.

Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma.
Ichikawa T, Suekane A, Nakahata S, Iha H, Shimoda K, Murakami T, Morishita K.
Int J Mol Sci. 2024;25:2842.

2023年

Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity.
Ishii T, Kobayakawa T, Matsuda K, Tsuji K, Ohashi N, Nakahata S, Noborio A, Yoshimura K, Mitsuya H, Maeda K, Tamamura H.
Eur J Med Chem. 2023;256:115449.

Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease.
Nozuma S, Matsuura E, Tanaka M, Kodama D, Matsuzaki T, Yoshimura A, Sakiyama Y, Nakahata S, Morishita K, Enose-Akahata Y, Jacoboson S, Kubota R, Takashima H.
JCI Insight. 2023;8:e167422.

Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations.
Mochida K, Nakahata S, Suzuki Y, Inoue K, Moriguchi S, Yamashita A, Amano M, Morishita K.
J Dermatol Sci. 2023:S0923-1811(23)00057-9.

2022年

The CGRP Receptor Antagonist MK0974 Induces EVI1high AML Cell Apoptosis by Disrupting ERK Signaling.
Suekane A, Ichikawa T, Saito Y, Nakahata S, Morishita K.
Anticancer Res. 2022;42(10):4743-4752.

Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors.
Manachai N, Rattanapinyopituk K, Fonghem P, Phoomvuthisarn P, Nakahata S, Morishita K, Rungsipipat A.
Vet Med Int. 2022;2022:9509900.

RAISING is a high-performance method for identifying random transgene integration sites.
Wada Y, Sato T, Hasegawa H, Matsudaira T, Nao N, Coler-Reilly ALG, Tasaka T, Yamauchi S, Okagawa T, Momose H, Tanio M, Kuramitsu M, Sasaki D, Matsumoto N, Yagishita N, Yamauchi J, Araya N, Tanabe K, Yamagishi M, Nakashima M, Nakahata S, Iha H, Ogata M, Muramatsu M, Imaizumi Y, Uchimaru K, Miyazaki Y, Konnai S, Yanagihara K, Morishita K, Watanabe T, Yamano Y, Saito M.
Commun Biol. 2022 Jun 2;5:535.

Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma.
Permatasari HK#, Nakahata S#(co-first author), Ichikawa T, Fauzi YR, Kiyonari H, Shide K, Kameda T, Shimoda K, Ono M, Taki T, Taniwaki M, Futakuchi M, Morishita K.
Exp Hematol. 2022;111:41-49. 

Integrin α6A (ITGA6A)-type Splice Variant in Extracellular Vesicles Has a Potential as a Novel Marker of the Early Recurrence of Pancreatic Cancer.
Asada T, Nakahata S, Fauzi YR, Ichikawa T, Inoue K, Shibata N, Fujii Y, Imamura N, Hiyoshi M, Nanashima A, Morishita K.
Anticancer Res. 2022;42:1763-1775.

2021年以前

Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
Fauzi YR, Nakahata S, Chilmi S, Ichikawa T, Nueangphuet P, Yamaguchi R, Nakamura T, Shimoda K, Morishita K.
PLoS One. 2021;16:e0256320.

A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo.
Saito M, Hasegawa H, Yamauchi S, Nakagawa S, Sasaki D, Nao N, Tanio M, Wada Y, Matsudaira T, Momose H, Kuramitsu M, Yamagishi M, Nakashima M, Nakahata S, Iha H, Ogata M, Imaizumi Y, Uchimaru K, Morishita K, Watanabe T, Miyazaki Y, Yanagihara K.
Int J Hematol. 2020;112:300-306.

Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
Chilmi S, Nakahata S, Fauzi YR, Ichikawa T, Tani C, Suwanruengsri M, Yamaguchi R, Matsuura T, Kurosawa G, Morishita K.
Int J Hematol. 2020;112:496-503.

Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
Nakahata S#, Syahrul C#(co-first author), Nakatake A, Sakamoto K, Yoshihama M, Nishikata I, Ukai Y, Matsuura T, Kameda T, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Ito A, Takemoto S, Nakano N, Saito M, Iwanaga M, Sagara Y, Mochida K, Amano M, Maeda K, Sueoka E, Okayama A, Utsunomiya A, Shimoda K, Watanabe T, Morishita K.
Haematologica. 2021;106:532-542.

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.
Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Mizuno Y, Kuwahara-Ota S, Kawaji Y, Taniwaki M, Inaba T, Tashiro K, Morishita K, Kuroda J.
Cancer Genomics Proteomics. 2020;17:77-89.

Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Ichikawa T, Shanab O, Nakahata S, Shimosaki S, Manachai N, Ono M, Iha H, Shimoda K, Morishita K.
Biochim Biophys Acta Mol Cell Res. 2020;1867:118615.

The regulation of NDRG2 expression during ATLL development after HTLV-1 infection.
Ichikawa T, Nakahata S, Fujii M, Iha H, Shimoda K, Morishita K.
Biochim Biophys Acta Mol Basis Dis. 2019;1865:2633-2646.

Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-κB.
Sarkar B, Nishikata I, Nakahata S, Ichikawa T, Shiraga T, Saha HR, Fujii M, Tanaka Y, Shimoda K, Morishita K.
Sci Rep. 2019;9:3491.

CGRP-CRLR/RAMP1 signal is important for stress-induced hematopoiesis.
Suekane A, Saito Y, Nakahata S, Ichikawa T, Ogoh H, Tsujikawa K, Morishita K.
Sci Rep. 2019;9:429.

Overexpression of absent in melanoma 2 in oral squamous cell carcinoma contributes to tumor progression.
Nakamura Y, Nakahata S, Kondo Y, Izumi A, Yamamoto K, Ichikawa T, Tamura T, Noumi K, Yamashita Y, Morishita K.
Biochem Biophys Res Commun. 2019,509:82-88.

Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.
Saha HR, Kaneda-Nakashima K, Shimosaki S, Suekane A, Sarkar B, Saito Y, Ogoh H, Nakahata S, Inoue K, Watanabe T, Nagase H, Morishita K.
Sci Rep. 2018,8:13741.

BCL11B is frequently downregulated in HTLV-1-infected T-cells through Tax-mediated proteasomal degradation.
Permatasari HK, Nakahata S, Ichikawa T, Morishita K.
Biochem Biophys Res Commun. 2017;490:1086-1092.

Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential.
Tamura T, Ichikawa T, Nakahata S, Kondo Y, Tagawa Y, Yamamoto K, Nagai K, Baba T, Yamaguchi R, Futakuchi M, Yamashita Y, Morishita K.
Cancer Res. 2017;77:2363-2374.

Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, Kubuki Y, Kurosawa G, Zhang L, Sudo Y, Shimoda K, Morishita K.
Biochem Biophys Res Commun. 2017;485:144-151.

Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N, Saito Y, Nakahata S, Bahirvani AG, Osato M, Morishita K.
Biochem Biophys Res Commun. 2017;482:994-1000.

Loss of NDRG2 enhanced activation of the NF-κB pathway by PTEN and NIK phosphorylation for ATL and other cancer development.
Ichikawa T, Nakahata S, Fujii M, Iha H, Morishita K.
Sci Rep. 2015;5:12841.

The loss of NDRG2 expression improves depressive behavior through increased phosphorylation of GSK3β.
Ichikawa T, Nakahata S, Tamura T, Manachai N, Morishita K.
Cell Signal. 2015;27:2087-2098.

Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
Nagai K, Nakahata S, Shimosaki S, Tamura T, Kondo Y, Baba T, Taki T, Taniwaki M, Kurosawa G, Sudo Y, Okada S, Sakoda S, Morishita K.
Cancer Med. 2014;3:1085-1099.

Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S#, Ichikawa T#(co-first author), Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K.
Nat Commun. 2014;5:3393.

Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56.
Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K.
Leukemia. 2013;27:1637-1649.

Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation.
Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K.
Cancer Sci. 2012;103:782-790.

Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma.
Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K.
Leukemia. 2012;26:1238-1246.

Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation.
Nishikata I, Nakahata S, Saito Y, Kaneda K, Ichihara E, Yamakawa N, Morishita K.
Oncogene. 2011;30:4194-4207.

CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K.
Leukemia. 2011;25:921-931.

Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Nakahata S, Yamazaki S, Nakauchi H, Morishita K.
Oncogene. 2010;29:4157-4169.

Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines.
Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K, Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K.
J Virol. 2010;84:6966-6977.

NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma.
Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K.
Biochem Biophys Res Commun. 2010;391:1785-1791.

Alteration of enhancer of polycomb 1 at 10p11.2 is one of the genetic events leading to development of adult T-cell leukemia/lymphoma.
Nakahata S, Saito Y, Hamasaki M, Hidaka T, Arai Y, Taki T, Taniwaki M, Morishita K.
Genes Chromosomes Cancer. 2009;48:768-776.

Artificial fertilization by intracytoplasmic sperm injection in a teleost fish, the medaka (Oryzias latipes).
Otani S, Iwai T, Nakahata S, Sakai C, Yamashita M.
Biol Reprod. 2009;80:175-183.

Critical role for TSLC1 expression in the growth and organ infiltration of adult T-cell leukemia cells in vivo.
Dewan MZ, Takamatsu N, Hidaka T, Hatakeyama K, Nakahata S, Fujisawa J, Katano H, Yamamoto N, Morishita K.
J Virol. 2008;82:11958-11963.

Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma.
Hidaka T#, Nakahata S#(co-first author), Hatakeyama K#(co-first author), Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K.
Blood. 2008;112:383-393.

Tissue-dependent isoforms of mammalian Fox-1 homologs are associated with tissue-specific splicing activities.
Nakahata S, Kawamoto S.
Nucleic Acids Res. 2005;33:2078-2089.

Involvement of Xenopus Pumilio in the translational regulation that is specific to cyclin B1 mRNA during oocyte maturation.
Nakahata S, Kotani T, Mita K, Kawasaki T, Katsu Y, Nagahama Y, Yamashita M.
Mech Dev. 2003;120:865-880.

Immunological detection and characterization of poly(A) polymerase, poly(A)-binding protein and cytoplasmic polyadenylation element-binding protein in goldfish and Xenopus oocytes.
Nakahata S, Mita K, Katsu Y, Nagahama Y, Yamashita M.
Zool Sci. 2001;18:337-343.

Biochemical identification of Xenopus Pumilio as a sequence-specific cyclin B1 mRNA-binding protein that physically interacts with a Nanos homolog, Xcat-2, and a cytoplasmic polyadenylation element-binding protein.
Nakahata S, Katsu Y, Mita K, Inoue K, Nagahama Y, Yamashita M.
J Biol Chem. 2001;276:20945-20953.

 

和文原著

乳房に数個のソフトボール大の腫瘤を認めた牛伝染性リンパ腫の1症例
谷千賀子、福家直幸、田角隆行、山口良二、中畑新吾、森下和広
産業動物臨床医学雑誌 13(1): 8-14 2022

英文総説

Pathophysiological significance of NDRG2 in cancer development through PP2A phosphorylation regulation.
Morishita K, Nakahata S, Ichikawa T.
Cancer Sci. 2021;112(1):22-30.

CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma.
Nakahata S, Morishita K.
J Clin Exp Hematop. 2012;52:17-22. 

和文総説

成人T細胞白血病/リンパ腫(ATLL)の発症機構
森下和広、中畑新吾
宮崎県医師会医学会誌42-2号 105-110頁 (2018年)

PTENリン酸化調節からみえたがん抑制遺伝子NDRG2の新たな機能
中畑新吾、森下和広　
生化学 89巻 877-880頁 (2017年)

ATL細胞におけるシグナル伝達機構と治療標的
中畑新吾、森下和広
血液内科 74巻 327-333頁（2017年）

ATLL発症機構解析研究の進歩
中畑新吾、森下和広
血液内科 71巻 244-249頁（2015年）

HTLV-1によるATLLの発症機序　
中畑新吾、森下和広
血液内科 63巻 389-398頁（2011年）

TCF8遺伝子発現抑制による成人T細胞白血病・リンパ腫発症機構
中畑新吾、森下和広　
血液フロンティア 18巻 65-72頁（2008年）

和文著書

成人T細胞白血病・リンパ腫の発症機構
中畑新吾、森下和広
造血器腫瘍アトラス〈第5版〉　日本医事新報社　345-352頁（2016年）

成人T細胞白血病/リンパ腫(ATLL)発症の分子機構
中畑新吾、森下和広　
日本臨床 73巻　日本臨床社　168-171頁（2015年）

ATLの発症機構
中畑新吾、森下和広
Annual Review血液　中外医学社 132-138頁（2010年）